Skip to content
DraconiticResearch
Search Sources API
182,544 studies31 sourcesUpdated 59 min ago
Peer-reviewedCC BY-NC 4.0Bio-protocol

Antiangiogenic Drug Testing Using Proangiogenic and Hypoxia Zebrafish Model

  • S. Vinoth1
  • Kirankumar Santhakumar1
  1. 1Zebrafish Genetics Laboratory, Department of Genetic Engineering, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, India
Read full textDOICite

Abstract

Zebrafish is an excellent in vivo model for high-throughput antiangiogenic drug testing, commonly known as the zebrafish angiogenesis assay. Conventional zebrafish angiogenesis assays are performed in wild-type zebrafish to evaluate the vascular changes in intersegmental and subintestinal vessel regions of the zebrafish larvae at 2 and 3 dpf stages, respectively. However, wild-type zebrafish larvae do not adequately mimic the hypoxia microenvironment and ectopic vessel branching characteristics of cancer. To overcome this limitation, we developed a genetically engineered zebrafish model with constitutive activation of the hypoxia signaling pathway by targeting the vhl, a tumor suppressor, by negative regulation of the hypoxia pathway, using CRISPR mutagenesis. This model exhibits robust ectopic blood vessel branching throughout the larval body, thereby recapitulating pathological angiogenesis. The utility of this zebrafish model system for drug screening was validated with the sorafenib treatment, a known antiangiogenic tyrosine kinase inhibitor. Overall, this proangiogenic hypoxia zebrafish model provides a physiologically relevant platform for testing antiangiogenic drugs.

Key features

• Generate a vhl mutant zebrafish line with constitutive activation of the hypoxia signaling pathway using CRISPR-CAS9 mutagenesis.

• The generated model exhibits extensive ectopic neovascular branching and abnormal vascular growth resembling pathological angiogenesis observed in solid tumors.

• Mimics the chronic hypoxic microenvironment commonly associated with cancer progression and angiogenesis.

• Provides an economical alternative to mammalian tumor models for early-stage antiangiogenic drug testing.

Related

  1. Remote control of wildtype zebrafish optomotor response with a photoswitchable drug
    Luisa Camerin, Joaquín Martínez-Tambella, Gregor Schuhknecht +5
    Frontiers in behavioral neurosciencePeer-reviewedCC BYFull textNeuroscienceEurope PMC
  2. A zebrafish model of NEXMIF-related encephalopathy identified drivers of hyperlocomotion and provides a scalable platform for drug discovery.
    Beatriz Bernal-Bermúdez, Francisco J Martínez-Morcillo, Inmaculada Fuentes-Martínez +4
    Frontiers in cell and developmental biologyPeer-reviewedCC BYFull textCell biologyEurope PMC
  3. Core needle biopsy-derived breast cancer microtumors enable functional drug-response testing for precision oncology
    Mooktapa Plikomol, Suphawat Laohawiriyakamol, Piyanun Wangkulangkul +6
    iSciencePeer-reviewedCC BY 4.0Full textCell biologyOncologyCell PressCrossrefEurope PMC
  4. Hypoxia and ascorbic acid: two interconnected microenvironmental factors driving collagen biosynthesis
    Méline Ricol, Oskar Lipinski, Catherine Moali +1
    Matrix BiologyPeer-reviewedCC BY 4.0Full text2 citedGeneral biologyHAL
  5. Hypoxia can set the elevational limits of dragonflies
    M. P. Moore, A. R. Brasket, M. J. Mokriski +2
    bioRxivPreprintAll rights reservedFull textEcologybioRxiv

Cite

BibTeXRIS
BibTeX
@article{vinoth2026antiangiogenic,
  title = {{Antiangiogenic Drug Testing Using Proangiogenic and Hypoxia Zebrafish Model}},
  author = {S. Vinoth and Kirankumar Santhakumar},
  journal = {Bio-protocol},
  year = {2026},
  month = oct,
  doi = {10.21769/bioprotoc.5846},
  url = {https://doi.org/10.21769/bioprotoc.5846},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Antiangiogenic Drug Testing Using Proangiogenic and Hypoxia Zebrafish Model
AU  - S. Vinoth
AU  - Kirankumar Santhakumar
PY  - 2026
DA  - 2026/10/20
JO  - Bio-protocol
DO  - 10.21769/bioprotoc.5846
UR  - https://doi.org/10.21769/bioprotoc.5846
AB  - Zebrafish is an excellent in vivo model for high-throughput antiangiogenic drug testing, commonly known as the zebrafish angiogenesis assay. Conventional zebrafish angiogenesis assays are performed in wild-type zebrafish to evaluate the vascular changes in intersegmental and subintestinal vessel regions of the zebrafish larvae at 2 and 3 dpf stages, respectively. However, wild-type zebrafish larvae do not adequately mimic the hypoxia microenvironment and ectopic vessel branching characteristics of cancer. To overcome this limitation, we developed a genetically engineered zebrafish model with constitutive activation of the hypoxia signaling pathway by targeting the vhl, a tumor suppressor, by negative regulation of the hypoxia pathway, using CRISPR mutagenesis. This model exhibits robust ectopic blood vessel branching throughout the larval body, thereby recapitulating pathological angiogenesis. The utility of this zebrafish model system for drug screening was validated with the sorafenib treatment, a known antiangiogenic tyrosine kinase inhibitor. Overall, this proangiogenic hypoxia zebrafish model provides a physiologically relevant platform for testing antiangiogenic drugs.  Key features  • Generate a vhl mutant zebrafish line with constitutive activation of the hypoxia signaling pathway using CRISPR-CAS9 mutagenesis.  • The generated model exhibits extensive ectopic neovascular branching and abnormal vascular growth resembling pathological angiogenesis observed in solid tumors.  • Mimics the chronic hypoxic microenvironment commonly associated with cancer progression and angiogenesis.  • Provides an economical alternative to mammalian tumor models for early-stage antiangiogenic drug testing.
SN  - 2331-8325
ER  -